ANTABIO logo

ANTABIO

Developing Tomorrow's Antibacterials

25 employees · est. 2009 · France

VS
ContraFect Corp logo

ContraFect Corp

...focused on discovering & developing differentiated biologic therapies for life-threatening, drug-resistant infections

10 employees · est. 2008 · Yonkers, United States

ContraFect Corp is the older company (2009 vs 2008); ANTABIO is the larger of the two.

Side-by-Side Comparison

ANTABIO ContraFect Corp
Founded
2009 2008 older
Headquarters
France Yonkers, United States
Employees
25 larger 10
Industry
Biotechnology, Life Sciences, Medical Devices Biotechnology, Health Care
Funding Stage
Series B Post Ipo Equity
Total Funding
$52.23M $249.07M
Funding Rounds
16 14
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Biopharmaceutical, Antibacterial Treatments, Drug-resistant Infections, Metalloenzymes Inhibitors, Bacterial Metallo ß-lactamases, Carbapenem Combination, Drug Discovery, Drug Development, Antibiotic Adjuvant, Nosocomial Infections, Clinical-stage, Wellcome Trust Seeding Drug Discovery Award, Labege, France Biologic Therapies, Drug-resistant Infections, Direct Lytic Agents, Lysins, Amurin Peptides, Antimicrobial-resistant Infections, Antibiotic-resistant Infections, Phase 2 Clinical Trial, Phase 3 Clinical Study, Breakthrough Therapy Designation, Monoclonal Antibodies, Multi-drug Resistant Infections, Biotechnology Company, Yonkers, New York
Website
antabio.com contrafect.com
ANTABIO logo

About ANTABIO

Antabio is a privately-held clinical-stage biopharmaceutical company founded in 2009, with a focus on developing novel and highly differentiated antibacterial treatments for drug-resistant infections. The company operates in the biotechnology, life sciences, and medical devices industries and is bas...

ContraFect Corp logo

About ContraFect Corp

ContraFect Corp is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infections. The company is addressing the pressing issue of antimicrobial-resistant infections, which account for an estimated 700,000 deaths worldw...

We will tell you when either one moves

BounceWatch watches ANTABIO and ContraFect Corp for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at ANTABIO and ContraFect Corp — by email.

Frequently Asked Questions

ANTABIO — Developing Tomorrow's Antibacterials. ContraFect Corp — ...focused on discovering & developing differentiated biologic therapies for life-threatening, drug-resistant infections. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
ANTABIO has raised $52.23M while ContraFect Corp has raised $249.07M.
ANTABIO and ContraFect Corp operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare ANTABIO with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at ANTABIO on 11 Sep 2024, and ContraFect Corp on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy